Literature DB >> 11514402

Instability of lipoprotein(a) in plasma stored at -70 degrees C: effects of concentration, apolipoprotein(a) genotype, and donor cardiovascular disease.

J M Simó1, J Camps, E Vilella, F Gómez, A Paul, J Joven.   

Abstract

BACKGROUND: There is considerable evidence to suggest that plasma lipoprotein(a) [Lp(a)] concentration is a cardiovascular risk factor. Confusing results in epidemiologic studies, however, suggest that the effects of storage should be further investigated. The influence of the assay method, the initial plasma Lp(a) concentration, and the apolipoprotein(a) [apo(a)] genotype are all factors that should be considered.
METHODS: Blood was obtained from 65 survivors of premature myocardial infarction and 95 age-matched controls. The plasma samples were stored in sterile conditions at -70 degrees C for 5 years in the presence of antioxidant and antiproteolytic substances. Plasma Lp(a) was measured by immunoturbidimetry, and apo(a) alleles were determined by pulsed-field gel electrophoresis and Southern blotting.
RESULTS: Plasma Lp(a) was significantly higher in patients. The mean kringle number for the smallest isoform was also lower in patients than in controls, but no differences were found in the distribution of the largest isoform. All patients and controls were heterozygotes. During storage, mean Lp(a) decreased significantly in samples from patients (-23%; P <0.001) but not in samples from controls (-9%; P, not significant). This was not related to the kringle number and was limited to samples with initial plasma Lp(a) concentrations between 41 and 345 mg/L.
CONCLUSIONS: Plasma Lp(a) from patients is less stable than Lp(a) from controls, and the difference is not related to distribution of apo(a) genotypes but may be concentration-dependent. Differential sample stability may complicate the interpretation of several studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11514402

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

1.  Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study.

Authors:  Yasuhiko Kubota; Aaron R Folsom; Christie M Ballantyne; Weihong Tang
Journal:  Atherosclerosis       Date:  2017-11-26       Impact factor: 5.162

Review 2.  The role of non-LDL:non-HDL particles in atherosclerosis.

Authors:  Jere P Segrest
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 3.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

4.  Effects of sample handling and storage on quantitative lipid analysis in human serum.

Authors:  Angela M Zivkovic; Michelle M Wiest; Uyen Thao Nguyen; Ryan Davis; Steven M Watkins; J Bruce German
Journal:  Metabolomics       Date:  2009-08-05       Impact factor: 4.290

5.  Lipoprotein(a) levels and risk of abdominal aortic aneurysm in the Women's Health Initiative.

Authors:  Elizabeth L Chou; Mary Pettinger; Bernhard Haring; Matthew W Mell; Mark A Hlatky; Jean Wactawski-Wende; Matthew A Allison; Robert A Wild; Aladdin H Shadyab; Robert B Wallace; Linda G Snetselaar; Matthew J Eagleton; Mark F Conrad; Simin Liu
Journal:  J Vasc Surg       Date:  2020-08-31       Impact factor: 4.268

6.  Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo.

Authors:  Marianne Månsson; Inge Kalies; Göran Bergström; Caroline Schmidt; Anne Legnehed; Lillemor Mattsson Hultén; Lena Amrot-Fors; David Gustafsson; Wolfgang Knecht
Journal:  Sci Rep       Date:  2014-06-17       Impact factor: 4.379

7.  Lipoprotein(a) and the Apolipoprotein B/A1 Ratio Independently Associate With Surgery for Aortic Stenosis Only in Patients With Concomitant Coronary Artery Disease.

Authors:  Johan Ljungberg; Anders Holmgren; Ingvar A Bergdahl; Johan Hultdin; Margareta Norberg; Ulf Näslund; Bengt Johansson; Stefan Söderberg
Journal:  J Am Heart Assoc       Date:  2017-12-15       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.